Dexcel Pharma Technologies Ltd.
CIK 1720007 · last filed 2022-11-14
Dexcel Pharma Technologies Ltd. is a corporate insider who has filed 12 SEC Form 4 insider transactions across 5 companies since 2017. The most recent filing shows the insider bought $20.0M of ROIVW on Nov 14, 2022. Across all open-market trades the lifetime net is +$18.4M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $11.0M across reported positions. The firm reports its address in Or Akiva, L3. 30 SEC filings were submitted jointly with Dan Oren.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ROIVW price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
OR AKIVA, L3 3060000
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. (ROIVW) Delisted | 10%+ Owner | 102,849,443 | $2.75 | $282.84M | $20.00M | 1 | 2022-11-14 |
| PLX | 10%+ Owner | 3,637,314 | $3.04 | $11.04M | -$2.09M | 1 | 2021-06-03 |
| Intec Pharma Ltd. (NTEC) Delisted | 10%+ Owner | 211,745 | $9.63 | $2.04M | -$281.7K | 1 | 2020-02-04 |
| Urovant Sciences Ltd. (UROV) Delisted | 10%+ Owner | 22,841,809 | $16.24 | $370.95M | $793.9K | 6 | 2019-06-14 |
| ABUS | 10%+ Owner | — | $4.08 | — | $0 | 2 | 2018-01-16 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| UROV | Roivant Sciences Ltd See footnotes |
22,841,809 | 100.0% | 2019-06-14 |
| Total | 22,841,809 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-11-14 | Roivant Sciences Ltd. (ROIVW) Delisted | Buy (P) | +4,000,000 | $20.00M | EDGAR |
| 2021-06-03 | PLX | Sell (S) | −918,717 | -$2.09M | EDGAR |
| 2020-02-04 | Intec Pharma Ltd. (NTEC) Delisted | Sell (S) | −915,951 | -$281.7K | EDGAR |
| 2019-06-14 | Urovant Sciences Ltd. (UROV) Delisted | Buy (P) | +22,011 | $177.3K | EDGAR |
| 2019-06-11 | Urovant Sciences Ltd. (UROV) Delisted | Buy (P) | +21,338 | $177.2K | EDGAR |
| 2019-06-06 | Urovant Sciences Ltd. (UROV) Delisted | Buy (P) | +21,122 | $166.0K | EDGAR |
| 2019-05-29 | Urovant Sciences Ltd. (UROV) Delisted | Buy (P) | +14,485 | $110.5K | EDGAR |
| 2019-05-28 | Urovant Sciences Ltd. (UROV) Delisted | Buy (P) | +9,835 | $77.8K | EDGAR |
| 2019-05-23 | Urovant Sciences Ltd. (UROV) Delisted | Buy (P) | +9,995 | $85.1K | EDGAR |
| 2018-06-07 | — | Buy (P) | +14,285,714 | $25.00M |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).